Mycenax Biotech Inc.

Strategic Positioning: Big D, Medium M
Mycenax (4726.TW) is a leading CDMO leveraging innovative development (D) with optimized manufacturing scale (M). We provide one-stop solutions for traditional biologics and emerging modalities such as ADC, allogeneic cell therapy, plasmid DNA.

Quality & Regulatory Excellence
Our core value lies in market-competitive technologies and cGMP-certified facilities. With numerous international approvals, we bridge the gap between R&D and commercial success.
 

Global Footprint 
With 70% of revenue from overseas, we are expanding from Asia-Pacific to Europe and the U.S. A key milestone occurred in 2025 when the company partnered with Japan’s Alfresa to establish Alfenax Biologic Corporation, accelerating our global strategic expansion.